Biopharmaceutical firm Insmed Incorporated has announced the grant of equity incentive awards to 103 newly hired employees, executed under Nasdaq Listing Rule 5635(c)(4). These awards were established as a material inducement to attract talent to join the company.

The incentives granted consist of 97,091 restricted stock units and options to purchase 12,850 shares of common stock, with an exercise price of $106.91 per share, which was the stock's closing price on the grant date.

The restricted stock units feature a four-year vesting schedule, commencing on the first day of the month following the grant date, with 25% vesting annually, contingent on the employee's continued service. The stock options have a ten-year term and also follow a four-year vesting schedule: 25% vest on the first anniversary of the start date, followed by 12.5% vesting every six months thereafter until fully vested on the fourth anniversary.

This marks the third significant incentive grant by Insmed within the past six months. In December 2025, the company granted equity to 92 new employees, followed by a grant to 85 new employees in March 2026. According to previously disclosed information, as of March 31, 2026, approximately 626,576 shares remained available for future grants under the company's 2025 Incentive Plan.

Insmed is in a pivotal phase of commercial expansion. The company reported first-quarter revenue of $306 million, with its core product, BRINSUPRI, contributing $207.9 million, representing a 44% sequential increase. The company has reaffirmed its full-year guidance for BRINSUPRI sales of at least $1 billion.

Nasdaq Rule 5635(c)(4) permits companies to grant equity to new employees without shareholder approval as a material inducement to their employment. This rule is designed to provide boards with flexibility in recruiting critical talent. Headquartered in Bridgewater, New Jersey, the company is focused on developing innovative therapies for rare diseases and maintains operations in Europe and Japan as well.